IN THE CLAIMS

Please amend the following claims.

1. (Thrice Amended) An enhanced bioavailable composition comprising a coprecipitate of cefuroxime axetil and a water-soluble excipient <u>made by dissolving pure crystalline cefuroxime axetil and the excipient in a suitable solvent, and recovering the co-precipitate, said composition having a disintegration time of at least 10 to 30 minutes and having a dissolution as determined by U.S. Pharmacopoeia 23rd Edition, of about 65% to about 80% in 20 minutes and about 80% to over 90% in 60 minutes.</u>

15. (Thrice Amended) An enhanced bioavailable composition comprising a coprecipitate of cefuroxime axetil and sorbital <u>made by dissolving pure crystalline</u> cefuroxime axetil and the sorbital in a suitable solvent, and recovering the coprecipitate, said composition having a disintegration time of at least 10 to 30 minutes and having a dissolution as determined by U.S. Pharmacopoeia 23rd Edition, of about 65% to about 80% in 20 minutes and about 80% to over 90% in 60 minutes.

REMARKS

Claims 1 to 20 now stand rejected under 35 USC 103(q) as being unpatentable by U.S. Patent No. 5,776,495 to Duclos *et al* in view of U.S. Patent No. 4,820,833 to Crisp *et al*.

In view of the above amendments, Applicant respectfully submits that the amended claims in all claims are clearly allowable over the prior art Duclos *et al* in view of Crisp *et al*.